The Retinoblastoma family member pRb2/p130 is an independent predictor survival in human soft tissue sarcomas

Valeria Masciullo, Ester Berardengo, Antonella Boglione, Alessandro Sgambato, Amelia Bernardi, Marco Forni, Alessandra Linari, Letizia Cito, Giovanni Scambia, Alessandro Comandone, Antonio Giordano

Research output: Contribution to journalArticle

Abstract

Purpose:pRb2/p130, a member of the Retinoblastoma gene family, has been shown to be a powerful prognostic factor in several malignancies. We sought to evaluate pRb2/p130 protein expression and its clinical effect in patients affected with soft tissue sarcomas (STS). Experimental Design: Expression of pRb2/p130 was evaluated by immunohistochemistry on formalin-fixed, paraffin-embedded sections in 41 STSs. Results obtained were correlated with clinicopathologic variables and disease-free and overall survival (OS) in univariate and multivariate analysis. Results: Expression of pRb2/p130 was diminished in 25 (61%) tumors, whereas the remaining ones (39%) were classified as high expressors. No correlation between pRb2/p130 expression and clinicopathologic variables was observed. However, a direct relationship between pRb2/p130 expression and clinical outcome of the patients was found in the subgroup of nonmetastatic tumors (n - 31). In univariate analysis, reduced pRb2/p130 expression was a negative prognostic factor and correlated with shorter disease-free survival (P = 0.021) and OS (P = 0.017) survival. In multivariate analysis, reduced pRb2/p130 expression was confirmed to be an independent predictor of shorter OS when considered together with tumor stage and grading (risk ratio, 7.893; confidence interval, 1.618-38.509; P = 0.011). Conclusions: This study shows for the first time the potential prognostic value of pRb2/130 expression evaluated on formalin-fixed, paraffin-embedded sections in STSs patients. pRb2/p130 immunoreactivity can be used to predict OS in patients with nonmetastatic STSs and, therefore, may represent a new prognostic marker.

Original languageEnglish
Pages (from-to)4775-4779
Number of pages5
JournalClinical Cancer Research
Volume14
Issue number15
DOIs
Publication statusPublished - Aug 1 2008

Fingerprint

Retinoblastoma
Sarcoma
Survival
Paraffin
Formaldehyde
Disease-Free Survival
Multivariate Analysis
Retinoblastoma Genes
Neoplasms
Neoplasm Grading
Research Design
Immunohistochemistry
Odds Ratio
Confidence Intervals
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Masciullo, V., Berardengo, E., Boglione, A., Sgambato, A., Bernardi, A., Forni, M., ... Giordano, A. (2008). The Retinoblastoma family member pRb2/p130 is an independent predictor survival in human soft tissue sarcomas. Clinical Cancer Research, 14(15), 4775-4779. https://doi.org/10.1158/1078-0432.CCR-07-4055

The Retinoblastoma family member pRb2/p130 is an independent predictor survival in human soft tissue sarcomas. / Masciullo, Valeria; Berardengo, Ester; Boglione, Antonella; Sgambato, Alessandro; Bernardi, Amelia; Forni, Marco; Linari, Alessandra; Cito, Letizia; Scambia, Giovanni; Comandone, Alessandro; Giordano, Antonio.

In: Clinical Cancer Research, Vol. 14, No. 15, 01.08.2008, p. 4775-4779.

Research output: Contribution to journalArticle

Masciullo, V, Berardengo, E, Boglione, A, Sgambato, A, Bernardi, A, Forni, M, Linari, A, Cito, L, Scambia, G, Comandone, A & Giordano, A 2008, 'The Retinoblastoma family member pRb2/p130 is an independent predictor survival in human soft tissue sarcomas', Clinical Cancer Research, vol. 14, no. 15, pp. 4775-4779. https://doi.org/10.1158/1078-0432.CCR-07-4055
Masciullo, Valeria ; Berardengo, Ester ; Boglione, Antonella ; Sgambato, Alessandro ; Bernardi, Amelia ; Forni, Marco ; Linari, Alessandra ; Cito, Letizia ; Scambia, Giovanni ; Comandone, Alessandro ; Giordano, Antonio. / The Retinoblastoma family member pRb2/p130 is an independent predictor survival in human soft tissue sarcomas. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 15. pp. 4775-4779.
@article{2812080ebb6841be856435152508bad5,
title = "The Retinoblastoma family member pRb2/p130 is an independent predictor survival in human soft tissue sarcomas",
abstract = "Purpose:pRb2/p130, a member of the Retinoblastoma gene family, has been shown to be a powerful prognostic factor in several malignancies. We sought to evaluate pRb2/p130 protein expression and its clinical effect in patients affected with soft tissue sarcomas (STS). Experimental Design: Expression of pRb2/p130 was evaluated by immunohistochemistry on formalin-fixed, paraffin-embedded sections in 41 STSs. Results obtained were correlated with clinicopathologic variables and disease-free and overall survival (OS) in univariate and multivariate analysis. Results: Expression of pRb2/p130 was diminished in 25 (61{\%}) tumors, whereas the remaining ones (39{\%}) were classified as high expressors. No correlation between pRb2/p130 expression and clinicopathologic variables was observed. However, a direct relationship between pRb2/p130 expression and clinical outcome of the patients was found in the subgroup of nonmetastatic tumors (n - 31). In univariate analysis, reduced pRb2/p130 expression was a negative prognostic factor and correlated with shorter disease-free survival (P = 0.021) and OS (P = 0.017) survival. In multivariate analysis, reduced pRb2/p130 expression was confirmed to be an independent predictor of shorter OS when considered together with tumor stage and grading (risk ratio, 7.893; confidence interval, 1.618-38.509; P = 0.011). Conclusions: This study shows for the first time the potential prognostic value of pRb2/130 expression evaluated on formalin-fixed, paraffin-embedded sections in STSs patients. pRb2/p130 immunoreactivity can be used to predict OS in patients with nonmetastatic STSs and, therefore, may represent a new prognostic marker.",
author = "Valeria Masciullo and Ester Berardengo and Antonella Boglione and Alessandro Sgambato and Amelia Bernardi and Marco Forni and Alessandra Linari and Letizia Cito and Giovanni Scambia and Alessandro Comandone and Antonio Giordano",
year = "2008",
month = "8",
day = "1",
doi = "10.1158/1078-0432.CCR-07-4055",
language = "English",
volume = "14",
pages = "4775--4779",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - The Retinoblastoma family member pRb2/p130 is an independent predictor survival in human soft tissue sarcomas

AU - Masciullo, Valeria

AU - Berardengo, Ester

AU - Boglione, Antonella

AU - Sgambato, Alessandro

AU - Bernardi, Amelia

AU - Forni, Marco

AU - Linari, Alessandra

AU - Cito, Letizia

AU - Scambia, Giovanni

AU - Comandone, Alessandro

AU - Giordano, Antonio

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Purpose:pRb2/p130, a member of the Retinoblastoma gene family, has been shown to be a powerful prognostic factor in several malignancies. We sought to evaluate pRb2/p130 protein expression and its clinical effect in patients affected with soft tissue sarcomas (STS). Experimental Design: Expression of pRb2/p130 was evaluated by immunohistochemistry on formalin-fixed, paraffin-embedded sections in 41 STSs. Results obtained were correlated with clinicopathologic variables and disease-free and overall survival (OS) in univariate and multivariate analysis. Results: Expression of pRb2/p130 was diminished in 25 (61%) tumors, whereas the remaining ones (39%) were classified as high expressors. No correlation between pRb2/p130 expression and clinicopathologic variables was observed. However, a direct relationship between pRb2/p130 expression and clinical outcome of the patients was found in the subgroup of nonmetastatic tumors (n - 31). In univariate analysis, reduced pRb2/p130 expression was a negative prognostic factor and correlated with shorter disease-free survival (P = 0.021) and OS (P = 0.017) survival. In multivariate analysis, reduced pRb2/p130 expression was confirmed to be an independent predictor of shorter OS when considered together with tumor stage and grading (risk ratio, 7.893; confidence interval, 1.618-38.509; P = 0.011). Conclusions: This study shows for the first time the potential prognostic value of pRb2/130 expression evaluated on formalin-fixed, paraffin-embedded sections in STSs patients. pRb2/p130 immunoreactivity can be used to predict OS in patients with nonmetastatic STSs and, therefore, may represent a new prognostic marker.

AB - Purpose:pRb2/p130, a member of the Retinoblastoma gene family, has been shown to be a powerful prognostic factor in several malignancies. We sought to evaluate pRb2/p130 protein expression and its clinical effect in patients affected with soft tissue sarcomas (STS). Experimental Design: Expression of pRb2/p130 was evaluated by immunohistochemistry on formalin-fixed, paraffin-embedded sections in 41 STSs. Results obtained were correlated with clinicopathologic variables and disease-free and overall survival (OS) in univariate and multivariate analysis. Results: Expression of pRb2/p130 was diminished in 25 (61%) tumors, whereas the remaining ones (39%) were classified as high expressors. No correlation between pRb2/p130 expression and clinicopathologic variables was observed. However, a direct relationship between pRb2/p130 expression and clinical outcome of the patients was found in the subgroup of nonmetastatic tumors (n - 31). In univariate analysis, reduced pRb2/p130 expression was a negative prognostic factor and correlated with shorter disease-free survival (P = 0.021) and OS (P = 0.017) survival. In multivariate analysis, reduced pRb2/p130 expression was confirmed to be an independent predictor of shorter OS when considered together with tumor stage and grading (risk ratio, 7.893; confidence interval, 1.618-38.509; P = 0.011). Conclusions: This study shows for the first time the potential prognostic value of pRb2/130 expression evaluated on formalin-fixed, paraffin-embedded sections in STSs patients. pRb2/p130 immunoreactivity can be used to predict OS in patients with nonmetastatic STSs and, therefore, may represent a new prognostic marker.

UR - http://www.scopus.com/inward/record.url?scp=51049109215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51049109215&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-4055

DO - 10.1158/1078-0432.CCR-07-4055

M3 - Article

C2 - 18676747

AN - SCOPUS:51049109215

VL - 14

SP - 4775

EP - 4779

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 15

ER -